Anticancer Drug Classification and Treatment
Introduction to Anticancer Drugs
- The American Society of Clinical Oncology and other guideline societies recommend classifying anticancer drugs based on their mechanism of action, site of action, and molecular targets, with main categories including cytotoxic chemotherapy, targeted therapy, immunotherapy, hormone therapy, and biological response modifiers 1
Types of Anticancer Therapies
- Targeted therapies, such as imatinib, erlotinib, and sunitinib, block specific enzymes and growth factor receptors, and are recommended by the National Comprehensive Cancer Network for certain types of cancer, with a moderate to high strength of evidence 1
- Immunotherapies, such as pembrolizumab and nivolumab, block proteins that prevent T cells from attacking cancer, and are recommended by the American Society of Clinical Oncology for certain types of cancer, with a high strength of evidence 2
- Hormone therapies, such as tamoxifen, block estrogen effects in breast tissue, and are recommended by the American Society of Clinical Oncology for hormone-dependent breast cancer, with a high strength of evidence 3, 4
- Biological response modifiers, such as interferon and interleukin-2, stimulate immune responses, and are recommended by the National Comprehensive Cancer Network for certain types of cancer, with a moderate strength of evidence 3
Treatment Recommendations
- The American Society of Clinical Oncology recommends trastuzumab, pertuzumab, and trastuzumab deruxtecan (T-DXd) for HER2-positive breast cancer, with significant benefits in improving outcomes for patients with HER2-positive disease 5
- The European Society for Medical Oncology also supports the use of HER2-targeted therapies for breast cancer 6
- The American Society of Clinical Oncology recommends immune checkpoint inhibitors like nivolumab, pembrolizumab, atezolizumab, and durvalumab for various cancers, with specific dosing schedules that may be modified during special circumstances 7
- The American Society of Clinical Oncology recommends chemotherapy protocols for colorectal, lung, and other cancers 8, 9
- The American Society of Hematology recommends DOACs like apixaban, edoxaban, and rivaroxaban over low molecular weight heparin (LMWH) for short-term treatment of venous thromboembolism in cancer patients 10
- The National Comprehensive Cancer Network also supports the use of anticoagulation strategies for cancer patients 11
Combination Therapies
- The National Comprehensive Cancer Network recommends combining agents from different classes, such as chemoimmunotherapy and targeted therapy with chemotherapy, to increase efficacy and manage toxicity, with a moderate to high strength of evidence 2, 4
- The European Society for Medical Oncology suggests that these combination therapies can be effective in treating certain types of cancer, with a moderate to high strength of evidence 2, 4
Toxicity and Adverse Events
- The National Comprehensive Cancer Network notes that different classes of anticancer drugs have distinct toxicity patterns, including myelosuppression, cardiotoxicity, and immune-related adverse events, with a high strength of evidence 12, 13, 14
- The American Society of Clinical Oncology recommends monitoring for these toxicities and adjusting treatment strategies accordingly, with a high strength of evidence 12, 13, 14